Acadia Pharmaceuticals Inc ACAD
We take great care to ensure that the data presented and summarized in this overview for ACADIA PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACAD
View all-
Baker Bros. Advisors LP New York, NY42.9MShares$783 Million8.72% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.9MShares$255 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$220 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.71MShares$159 Million2.61% of portfolio
-
Morgan Stanley New York, NY7.3MShares$133 Million0.01% of portfolio
-
State Street Corp Boston, MA4.52MShares$82.6 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.24MShares$59.2 Million0.05% of portfolio
-
Goldman Sachs Group Inc New York, NY2.88MShares$52.6 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA2.88MShares$52.5 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA2.75MShares$50.2 Million8.06% of portfolio
Latest Institutional Activity in ACAD
Top Purchases
Top Sells
About ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Transactions at ACAD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 24
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
773
-1.41%
|
$14,687
$19.96 P/Share
|
|
Feb 24
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
475
-2.29%
|
$9,025
$19.96 P/Share
|
|
Feb 23
2025
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,353
+2.42%
|
-
|
|
Feb 23
2025
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
840
+3.9%
|
-
|
|
Nov 19
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,259
-16.14%
|
$164,144
$16.81 P/Share
|
|
Nov 19
2024
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
4,073
-17.02%
|
$65,168
$16.81 P/Share
|
|
Nov 19
2024
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
SELL
Open market or private sale
|
Direct |
10,329
-14.26%
|
$165,264
$16.81 P/Share
|
|
Nov 17
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
19,826
+14.54%
|
-
|
|
Nov 17
2024
|
James Kihara PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,930
+15.39%
|
-
|
|
Nov 17
2024
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
BUY
Exercise of conversion of derivative security
|
Direct |
19,826
+12.86%
|
-
|
|
Oct 12
2024
|
Adora Ndu |
BUY
Exercise of conversion of derivative security
|
Direct |
4,381
+22.13%
|
-
|
|
Aug 19
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
9,733
-18.2%
|
$145,995
$15.28 P/Share
|
|
Aug 19
2024
|
Stephen Davis CEO |
SELL
Open market or private sale
|
Direct |
31,747
-14.54%
|
$476,205
$15.28 P/Share
|
|
Aug 19
2024
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
SELL
Open market or private sale
|
Direct |
9,534
-15.45%
|
$143,010
$15.28 P/Share
|
|
Aug 16
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
18,904
+16.0%
|
-
|
|
Aug 16
2024
|
Stephen Davis CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,115
+13.05%
|
-
|
|
Aug 16
2024
|
Brendan Teehan EVP, COO, HEAD OF COMMERCIAL |
BUY
Grant, award, or other acquisition
|
Direct |
18,653
+13.78%
|
-
|
|
Jun 10
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
975
-2.74%
|
$13,650
$14.79 P/Share
|
|
Jun 08
2024
|
Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,893
+5.06%
|
-
|
|
May 29
2024
|
Laura Brege |
BUY
Exercise of conversion of derivative security
|
Direct |
6,652
+24.82%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 192K shares |
|---|---|
| Exercise of conversion of derivative security | 200K shares |
| Open market or private sale | 160K shares |
|---|